## East Bridge Capital Master Fund Ltd

C/o Citco (Mauritius) Limited, 4th Floor, Tower A, 1Cybercity Ebène, Mauritius Tel: (230) 404 2600

17 March, 2020

Bombay Stock Exchange Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Fax: +91- 22- 22723121 Tel: +91-22- 22721233/34 Ext. 8013/ 8184/ 8332

Email:

corp.relations@bseindia.com

Dear Sir:

Re: Reporting of acquisition of shares of Jubilant Life Sciences Ltd

Please find attached the relevant disclosure forms as per Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 pursuant to change in shareholding in excess of 2% of total shareholding in the target company from the last disclosure in respect of the above mentioned. The last disclosure in this regard was made on 30 July 2019.

The originals are being couriered to you today.

Thank you for your attention.

Yours faithfully

Cory Pavlik Director



## **ANNEXURE-2**

## Format for Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

## Part-A- Details of the Acquisition

Name of the Target Company (TC)	Jubilant Life Sciences Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	East Bridge Capital Master Fund Ltd. East Bridge Capital Master Fund I Ltd.		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	Bombay Stock Exchange Limited National Stock Exchange of India Limited		
Details of the acquisition/disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of: a) Shares carrying voting rights	11,583,055	7.27%	7.27%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
c) Voting rights (VR) otherwise than by equity shares	0	0%	0%
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0	0%	0%
e) Total (a+b+c+d)	11,583,055	7.27%	7.27%
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	1,157,078	0.73%	0.73%
b) VRs acquired/sold otherwise than by equity shares	0	0%	0%
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying	0	0%	0%

भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

E DI COCCITTOS CITO EXCI	idilde	Duale	o mala	
voting rights in the TC (specify holding in each category) acquired/sold				
d) Shares encumbered / invoked/released by the acquirer	0	0%	0%	
e) Total (a+b+c+d)	1,157,078	0.73%	0.73%	
After the acquisition/sale, holding of:			·	
a) Shares carrying voting rights	12,740,133	8.00%	8.00%	
b) Shares encumbered with the acquirer	0	0%	0%	
c) VRs otherwise than by equity shares	0	0%	0%	
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	0	0%	0%	
e) Total (a+b+c+d)	12,740,133	8.00%	8.00%	
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer etc.)	Market Transaction			
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	17 March 2020			
Equity share capital / total voting capital of the TC before the said acquisition/sale	159,281,139			
Equity share capital/ total voting capital of the TC after the said acquisition/sale	159,281,139			
Total diluted share/voting capital of the TC after the said acquisition	0			

<sup>(\*)</sup> Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the acquirer / Authorised Signatory

Place: Boston, MA

Date: March 17,2020